12 results about "Coagulopathy" patented technology

Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.

A coagulation test device for measuring clot time and clot characteristics of whole blood samples under different hemostatic conditions. The test results are used as an aid in the management of patients with unexplained coagulopathy for the purpose of helping the physician to determine appropriate clinical measures to hemostasis in the patient.

This invention relates to MASP isotypes as inhibitors of complement activation. It also relates to novel ficolin-related peptides and peptides derived from these ficolin-related peptides for the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombosis, or coagulopathy, and for use as biomarkers. Furthermore, this invention relates to antibodies recognizing the novel ficolin-related peptides and peptides derived therefrom, nucleic acid molecules encoding the peptides, vectors for producing the peptides, and host cells.

The application belongs to the technical field of biological medicine, and particularly relates to application of a detection LGALS2 gene reagent in preparation of a reagent kit for detecting sepsis coagulopathy. The product diagnoses sepsis coagulopathy by detecting the transcription level of the LGALS2 gene in a sample, and when the transcription level of the LGALS2 gene is significantly reduced, the subject has sepsis coagulopathy. The application uses LGALS2 as a biomarker, and through a human experiment verification, the transcription level of peripheral blood LGALS2 of a sepsis coagulopathy patient is significantly lower than that of a patient without sepsis coagulopathy. The transcription level of LGALS2 in whole blood RNA has high specificity and sensitivity in diagnosis and prediction of the risk of sepsis coagulopathy. The LGALS2 gene and the transcription level thereof can be used for preparation of a reagent or a kit for early diagnosis of sepsis coagulopathy, provide reference information for giving individualized intervention treatment, and have important clinical application value and popularization.

The invention pertains to a therapeutic formulation, CARDIOGARDIA, for the management of cardiac arrest. The formulation co-formulates selected microRNAs, including miR-21, miR-1, miR-29, miR-17, and miR-133, and antithrombin and essential electrolytes in a single formulation. The different components in combination target various pathological processes associated with cardiac arrest, including fibrosis, apoptosis, arrhythmia, and coagulopathy. Delivery may be affected by suitable pharmaceutical vehicles or carriers to enable effective delivery. By acting on these distinct pathological processes in combination, the formulation provides a multifaceted approach to stabilizing cardiac function and improving resuscitation outcome. The invention further encompasses methods of treating subjects experiencing cardiac arrest by administering the formulation in therapeutically effective amounts.

The present invention relates to bispecific antibodies capable of binding to coagulation Factor IX (FIX) and / or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and / or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A with or without inhibitors.

A device for performing coagulation tests that measure clotting time and clot characteristics in a whole blood sample under different hemostatic conditions. The test results are used to aid in the management of patients with coagulopathy of unknown etiology, helping the physician determine the appropriate clinical action to stop bleeding.

The invention relates to the technical field of auxiliary hemostasis devices, and discloses an emergency auxiliary hemostasis device for a blood coagulation dysfunction patient, which comprises a fixing plate I, a drug delivery mechanism arranged on the inner side of the fixing plate I, a compression mechanism arranged at the bottom of the fixing plate I, and a fixing mechanism arranged on the inner side of the fixing plate I, the fixing mechanism is arranged at the bottom of the first fixing plate, and the dosing mechanism comprises a hemostasis assembly. According to the hemostasis device, the hemostasis assembly is arranged, specifically, when a rotating sleeve rotates, a rotating ring is driven to rotate, a first sliding rod at the bottom of the rotating sleeve slides in a sliding groove, a sliding plate is pushed to be separated towards the two sides along a sliding rail, a second fixing plate extrudes a telescopic rod and a first spring, medicine in a fixing sleeve is released, and after releasing is completed, the rotating sleeve is loosened; under the elastic reset action of the telescopic rod and the first spring, the second fixing plate and the sliding plate are close to each other, the bottom of the fixing sleeve is closed, the utilization efficiency of hemostatic medicine is improved, and a hemostatic environment is rapidly formed.

The present disclosure provides combinations of tissue plasminogen activator mutant / s and lysine analogs and compositions thereof for inhibiting fibrinolysis induced by free plasmin. The present disclosure further provides kits, uses and methods for treating coagulopathy associated with anti-fibrinolytic therapy.

Methods of treating coagulopathy using a bispecific antibody comprising (i) a first antigen-binding site capable of binding Factor Vll(a), and (ii) a second antigen-binding site capable of binding TREM-like Transcript 1 (TLT-1).

Clinically validated methods of administering Yunnan Baiyao or Xingnaojing can improve postoperative recovery and long-term clinical prognosis of patients with moderate-to-severe traumatic brain injury (TBI) and emergency craniotomy. Both medicinal methods are useful for minimizing or inhibiting the adverse impacts of secondary injury, oxidative damage and neuroinflammation associated with TBI, spinal cord injury, craniotomy / craniectomy, cerebral hemostasis and hemorrhage, coagulopathy, stroke, neural injury and neuroinflammation, and for promoting the long-term functional recovery and well-being of the patients with the afore-mentioned diseases.

A use of a S protein or P4HB protein as a target in preparation of a drug for prevention or treatment of coagulopathy associated with SARS-CoV-2 infection. The S protein is the spike protein of SARS-CoV-2 virus, and the P4HB protein is human protein disulfide isomerase. By means of integrated proteomic and bioinformatic study on SARS-CoV-2 interaction networks in endothelial cells, pulmonary cells, and bronchial cells, the S protein is determined as a key contributor to the procoagulant characteristics of viruses, and the S protein plays a critical role in inducing endothelial cell dysfunction. The S protein directly interacts with P4HB by means of an RBM region thereof, and promotes the secretion of P4HB by means of a lysosomal secretion pathway, thereby promoting thrombosis both in vitro and in a mouse model. Genetic or pharmacological targeting of S-P4HB axis can alleviate coagulopathy in a mouse model. The level of P4HB and disulfide bonds of target proteins thereof are significantly altered in the plasma and leukocytes of COVID-19 patients and are closely associated with the disease severity and coagulation correlation of these patients.